Home Critical engine NeuShen Therapeutics closes pre-A funding with approximately $20 million

NeuShen Therapeutics closes pre-A funding with approximately $20 million

  • Closing of the pre-A financing round led by LAMPAM Capital
  • Dual in-house small molecule discovery and AAV-based gene therapy platform targeting neurological and psychiatric disorders

SHANGHAI, Sept. 29, 2022 /PRNewswire/ — NeuShen Therapeutics, Inc., a biotechnology company focused on developing innovative treatments for central nervous system (CNS) disorders with dual platforms of AAV-based gene therapy and small molecule discovery, announced today the closing of a pre-A series funding of approximately $20 million led by LAPAM, a China-based venture capital firm. NeuShen was founded by a group of industry executives who have extensive global experience in central nervous system (CNS) drug development. The new capital will be used to expand the team and catalyze CNS drug discovery internally in the US and China.

“The success of this fundraising is a testament to our team’s ability to accomplish CNS drug development and re-ignite our discovery engine to build a pipeline with AAV-based small molecule and gene therapy programs. said Joan Shen, MD, Ph.D., CEO and Founder of NeuShen. “CNS disease is an area with huge unmet needs. Our company has had a very clear goal from day one, which is to develop new therapies to relieve the burden of patients with CNS disorders. months, we have developed an achievable R&D strategy and established a substantial core team with experienced CNS drug hunters Significant progress has been made in building the internal small molecule pipeline and new AAV gene therapy programs In addition, multiple collaborations and partnerships were discussed and established.

CNS disorders are increasingly recognized as leading causes of death and disability worldwide, while diagnosis and treatment have lagged far behind. Urgent action is needed to meet the growing challenges. “By bringing breakthroughs and lessons learned from other disease targets such as ophthalmology, oncology and hematology, we believe that AAV-based gene therapy represents a new opportunity in the treatment of brain disorders. SNC. My colleagues and I at the Horae Gene Therapy Center look forward to working with Neushen to explore these treatment opportunities. NeuShen’s team’s experiments in neuroscience will be key to achieving this,” noted Dr. Guangping Gao , Professor, Director, Horae Gene Therapy Center, UMass Chan Medical School Collaborations between NeuShen and UMass are currently under discussion, which will include several CNS gene therapy projects.

“We are very pleased to partner with NeuShen from the beginning. Lapam Capital has a strong commitment to healthcare, and we believe the CNS therapeutic area will attract more investment, given the huge unmet needs and scientific advancements in the field. We highly value Dr. Joan Shen and her management team for their expertise. Lampam Capital is confident in NeuShen’s ability to be a leading player in the development of innovative therapies for CNS diseases. said Mr. Zhihua Yu, Managing Director of Lapam Capital.

“Dr. Shen has brought together a preeminent group of scientists, clinicians and drug developers to build a global biotech developing new drugs for unmet needs in CNS therapeutic areas. TTM Capital is delighted to support Neushen in building of its multi-modality pipelines to help patients around the world,” said Ms. Lilly Zhang, Founder and Managing Partner of TTM Capital.

About NeuShen Therapeutics

NeuShen Therapeutics is a biotechnology company focused on the research and development of innovative drugs to treat CNS disorders, applying dual research platforms including AAV-based gene therapy and the discovery of small molecules. With operations in Shanghai, China and Boston, MA, NeuShen has a world-class team and is honored to be advised by an outstanding Board of Directors and Scientific Advisory Board.


About Lapam Capital

Beijing-based Lapam Capital is one of China’s leading healthcare venture capital firms. Lapam currently manages five RMB funds and one USD fund, with over RMB 10 billion under management. Lapam Capital focuses on investing in fast-growing early to mid-stage companies that have innovative pharmaceuticals and medical devices. It has invested in approximately 60 biopharmaceutical companies and 10 medical device companies to date, including Betta Pharma, RemeGen Co. Ltd., Clover Biopharmaceuticals, Yahong Meditech, Stemirna Therapeutics, Binhui Biotech, ImmuneOnco Biopharmaceuticals, Biostar Pharmaceuticals, Aibo Medical Robot Co. .Ltd. .and many other companies with great potential. Lapam Capital has a professional investment team with more than 20 years of R&D and management experience in the international and domestic biopharmaceutical industry and can provide comprehensive value-added support to invested companies.

About TTM Capital

TTM Capital is an investment company specializing in the healthcare sector in China and around the world. We focus on early-stage and growth-stage companies, including the pharmaceutical, biotech and medical technology sub-sectors.

The TTM Capital team is comprised of seasoned, globally minded investment professionals with extensive industry experience, who work together to deliver superior and consistent returns for the firm’s investors. We are committed to accumulating industry experience over time, with the goal of developing an ecosystem of expertise to build transformative healthcare businesses.

Quote Show original content to download multimedia:https://www.prnewswire.com/news-releases/neushen-therapeutics-closes-pre-a-financing-with-20m-301636539.html

SOURCE NeuShen Therapeutic